Finch Therapeutics Group Inc.

14.29+0.5200+3.78%Vol 118.04K1Y Perf -33.40%
Jun 16th, 2021 16:00 DELAYED
BID14.28 ASK14.55
Open14.16 Previous Close13.77
Pre-Market- After-Market-
 - -  - -%
Target Price
29.33 
Analyst Rating
— — 0.00
Potential %
105.25 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+ —    59.51
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap677.63M 
Earnings Rating
Price Range Ratio 52W %
24.95 
Earnings Date
12th Aug 2021

Today's Price Range

13.5114.70

52W Range

11.5622.50

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
7.20%
1 Month
6.32%
3 Months
-32.97%
6 Months
-
1 Year
-33.40%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FNCH14.290.52003.78
AAPL130.46-1.3300-1.01
GOOG2 511.35-16.0700-0.64
MSFT259.43-1.4700-0.56
XOM60.40-1.5900-2.56
WFC41.75-1.0400-2.43
JNJ161.98-3.2400-1.96
FB329.66-6.8500-2.04
GE12.78-0.2200-1.69
JPM147.92-3.8400-2.53
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.23-1.00-334.78
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2021
Estimated EPS Next Report-0.28
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume118.04K
Shares Outstanding47.42M
Trades Count1.26K
Dollar Volume0
Avg. Volume106.95K
Avg. Weekly Volume50.87K
Avg. Monthly Volume41.94K
Avg. Quarterly Volume106.95K

Finch Therapeutics Group Inc. (NASDAQ: FNCH) stock closed at 16 per share at the end of the most recent trading day (a 3.78% change compared to the prior day closing price) with a volume of 374.17K shares and market capitalization of 677.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 131 people. Finch Therapeutics Group Inc. CEO is Mark Smith.

The one-year performance of Finch Therapeutics Group Inc. stock is -33.4%, while year-to-date (YTD) performance is %. FNCH stock has a five-year performance of %. Its 52-week range is between 11.56 and 22.5, which gives FNCH stock a 52-week price range ratio of 24.95%

Finch Therapeutics Group Inc. currently has a PE ratio of -7.00, a price-to-book (PB) ratio of 2.64, a price-to-sale (PS) ratio of 67.58, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -17.08%, a ROC of -18.83% and a ROE of -18.97%. The company’s profit margin is -%, its EBITDA margin is -469.90%, and its revenue ttm is $9.48 Million , which makes it $0.20 revenue per share.

Of the last four earnings reports from Finch Therapeutics Group Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Finch Therapeutics Group Inc.’s next earnings report date is 12th Aug 2021.

The consensus rating of Wall Street analysts for Finch Therapeutics Group Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Finch Therapeutics Group Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Finch Therapeutics Group Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Finch Therapeutics Group Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 62.11, ATR14 : 1.17, CCI20 : 13.48, Chaikin Money Flow : -0.30, MACD : -0.07, Money Flow Index : 60.78, ROC : -2.06, RSI : 53.83, STOCH (14,3) : 17.18, STOCH RSI : 1.00, UO : 34.78, Williams %R : -82.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Finch Therapeutics Group Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Finch Therapeutics Group Inc.

Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.

CEO: Mark Smith

Telephone: +1 617 229-6499

Address: 200 Inner Belt Road, Somerville 02143, MA, US

Number of employees: 131

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits